Targeting Gq pathway in uveal melanoma
葡萄膜黑色素瘤中的靶向 Gq 通路
基本信息
- 批准号:10700134
- 负责人:
- 金额:$ 44.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-07 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:Automobile DrivingBRAF geneBuffersCRISPR/Cas technologyCardiolipinsCell ProliferationCell SurvivalCellsClinicalCombined Modality TherapyCoupledDataDependenceDevelopmentDiglyceridesDiseaseDisease modelEndothelinEndothelin-1EngineeringEnvironmentEnzymesExposure toEyeFamily memberFeedbackG-Protein-Coupled ReceptorsGNAQ geneGene MutationGenesGenetic EngineeringGoalsImmune checkpoint inhibitorIn VitroKnock-in MouseKnock-outKnockout MiceLigandsLipid Synthesis PathwayLipidsLiverMalignant NeoplasmsMass Spectrum AnalysisMediatingMelanoma CellMetastatic Neoplasm to the LiverMetastatic toMethodsMitogen-Activated Protein KinasesMutationNF1 geneNatureNeoplasm MetastasisOncogenicPathway interactionsPatientsPhenotypePhosphatidylinositolsPhospholipase CPhosphorylationProtein Kinase CProtein Kinase C InhibitorRegimenRegulationResistanceRoleSecond Messenger SystemsSignal PathwaySignal TransductionSomatic MutationTestingTherapeuticTherapeutic EffectTreatment EfficacyUnited StatesUp-RegulationUveal MelanomaWorkXenograft ModelXenograft procedureclinical efficacyclinically relevanteffective therapyexperimental studygenome-wideimmune checkpoint blockadeimprovedin vivoinhibitorloss of functionmelanocytemelanomamortalitymouse modelnew therapeutic targetnovelnovel therapeutic interventionoverexpressionphosphatidatephosphatidylcholine-specific phospholipase Cphosphoproteomicsreceptorresistance mechanismsubcutaneoussuccesstargeted treatmenttherapeutic targettherapeutically effectivetranscriptional reprogrammingtranscriptome sequencingtumor
项目摘要
Project summary:
Uveal melanoma (UM) is the most common intraocular cancer in the United States and accounts for about
5% of all kinds of melanomas. Approximate 50% of UM patients develop metastases, predominantly to the liver
with 100% mortality. UM lacks mutations in BRAF, NRAS, NF1 and KIT common to other melanoma types.
Instead, over 90% harbor somatic activating mutations in the Gaq family members GNAQ or GNA11, with the
remainder carrying mutations of genes also acting in the Gaq signaling pathway such as CYSLTR2, a Gaq-
coupled GPCR, phospholipases C b4 (PLCb4), a direct effector of Gaq. Therefore, UM is genetically defined by
activating mutations of the Gaq pathway. Despite dramatic successes in other melanoma subtypes, immune
checkpoint inhibitors and targeted therapies have failed to demonstrate clinical benefits in UM, leading to an
urgent need to develop novel and effective therapeutic regimens. The CYSLTR2->Gaq->PLCb-> protein kinase
C (PKC) module is a linear signaling cascade that drives the essential MAP-kinase (MAPK) signaling for UM cell
proliferation, making Gaq pathway the prime target for targeted therapy for this devasting disease. Although both
GNAQ/11 and PKC inhibitors are very effective to suppress UM cell proliferation/survival in vitro, targeting either
GNAQ/11 or PKC alone has shown limited efficacy in UM liver metastasis. Understanding the resistance to the
Gaq pathway inhibition is of paramount importance to develop new strategies that work in the specific signaling
context of a constitutively activated Gaq pathway. Our preliminary data show either GNAQ/11 inhibition or PKC
inhibition yields strong upregulation of the Gaq-coupled receptor EDNRB, which when encountering its ligand
EDN1 from the liver environment can lead to reactivation of MAPK, thus driving resistance to Gaq pathway
inhibition in UM. In this proposal, we will evaluate that blocking endothelin signaling will increase the therapeutic
efficacy of targeting oncogenic Gaq signaling, directly or downstream, using newly developed genetically
engineered and xenograft models of UM metastatic to the liver. While the role of endothelin signaling in
melanocyte development and melanoma progression is well documented, the nature of the feedback that
upregulates EDNRB expression/signaling is not understood. We will utilize a combination of candidate
approaches, RNAseq and phospho-proteomics to dissect the underlying mechanisms in UM cells and in
melanocytes. Our preliminary data also show that secondary mutations in GNA11 can confer resistance to the
Gaq inhibition. In this proposal, we will expand the emerging landscape of the mechanism underlying the
adaptive and acquired resistance to Gaq pathway inhibition and identify rational therapy combinations to improve
the therapeutic efficacy for metastatic UM. Using a combined genome-wide CRISPR/Cas9 synthetic lethality
screen and phospho-proteomic screen we identified a lipid synthesis pathway that is essential for the survival of
cells with Gaq mutation, which we will explore as entirely novel therapeutic target for UM.
项目概要:
葡萄膜黑色素瘤(UM)是美国最常见的眼内癌症,
占所有黑色素瘤的5%。大约50%的UM患者发生转移,主要转移至肝脏
死亡率百分之百UM缺乏其他黑色素瘤类型常见的BRAF、NRAS、NF1和KIT突变。
相反,超过90%的人在Gaq家族成员GNAQ或GNA11中携带体细胞激活突变,
其余携带也在Gaq信号传导途径中起作用的基因突变,如CYSLTR2,一种Gaq-
偶联GPCR,磷脂酶Cb4(PLCb4),Gaq的直接效应物。因此,UM在基因上被定义为
激活Gaq途径的突变。尽管在其他黑色素瘤亚型中取得了巨大的成功,但免疫
检查点抑制剂和靶向治疗未能证明UM的临床益处,导致
迫切需要开发新的和有效的治疗方案。CYSLTR2-> Gaq-> PLCb->蛋白激酶
蛋白激酶C(PKC)模块是一个线性信号级联反应,驱动UM细胞必需的MAPK信号通路
增殖,使Gaq途径成为这种毁灭性疾病靶向治疗的主要靶点。虽然两
GNAQ/11和PKC抑制剂在体外非常有效地抑制UM细胞增殖/存活,靶向
GNAQ/11或PKC单独在UM肝转移中显示出有限的功效。了解对
抑制Gaq通路对于开发在特异性信号传导中起作用的新策略至关重要
在组成性激活的Gaq途径的背景下。我们的初步数据显示,GNAQ/11抑制或PKC
抑制产生Gaq偶联受体EDNRB的强烈上调,当遇到其配体时,
来自肝脏环境的EDN1可以导致MAPK的重新激活,从而驱动对Gaq途径的抗性
在UM中抑制。在这个建议中,我们将评估阻断内皮素信号传导将增加治疗效果。
使用新开发的基因工程技术,直接或下游靶向致癌Gaq信号传导的功效
转移到肝脏的UM的工程化和异种移植模型。虽然内皮素信号在
黑素细胞发育和黑色素瘤进展是有据可查的,
上调EDNRB表达/信号传导尚不清楚。我们将利用候选人的组合
方法,RNAseq和磷酸化蛋白质组学来剖析UM细胞中的潜在机制,
黑素细胞我们的初步数据还表明,GNA11中的继发性突变可以赋予对GNA11的耐药性。
Gaq抑制。在本提案中,我们将扩大作为《公约》基础的机制的新格局,
对Gaq通路抑制的适应性和获得性耐药性,并确定合理的治疗组合,以改善
转移性UM的治疗效果。使用组合的全基因组CRISPR/Cas9合成致死性
筛选和磷酸化蛋白质组学筛选,我们确定了一个脂质合成途径,这是必不可少的生存,
Gaq突变的细胞,我们将探索作为UM的全新治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xu Chen其他文献
Xu Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xu Chen', 18)}}的其他基金
RasGRP3 and Protein Kinase D as therapeutic targets for Uveal Melanoma
RasGRP3 和蛋白激酶 D 作为葡萄膜黑色素瘤的治疗靶点
- 批准号:
10584705 - 财政年份:2023
- 资助金额:
$ 44.52万 - 项目类别:
Mechanisms by which the ketone body β-hydroxybutyrate counteracts tau pathogenesis
酮体β-羟基丁酸抵消 tau 发病机制的机制
- 批准号:
10449007 - 财政年份:2022
- 资助金额:
$ 44.52万 - 项目类别:
Role of Testosterone in Modulating Tau Pathogenesis in Females
睾酮在调节女性 Tau 发病机制中的作用
- 批准号:
10685501 - 财政年份:2022
- 资助金额:
$ 44.52万 - 项目类别:
Mechanisms by which the ketone body β-hydroxybutyrate counteracts tau pathogenesis
酮体β-羟基丁酸抵消 tau 发病机制的机制
- 批准号:
10612459 - 财政年份:2022
- 资助金额:
$ 44.52万 - 项目类别:
The Role of Chromogranin A in Tauopathy
嗜铬粒蛋白 A 在 Tau 蛋白病中的作用
- 批准号:
10214077 - 财政年份:2021
- 资助金额:
$ 44.52万 - 项目类别:
Metabolic Regulation of Neurodegeneration in Tauopathy
Tau 蛋白病神经变性的代谢调节
- 批准号:
9321947 - 财政年份:2016
- 资助金额:
$ 44.52万 - 项目类别:
相似海外基金
BRAF gene mutation causes hallmarks of cancer associated with tumor microenvironment
BRAF基因突变导致与肿瘤微环境相关的癌症特征
- 批准号:
18K14582 - 财政年份:2018
- 资助金额:
$ 44.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Significance of BRAF gene mutation on tumor microenvironment
BRAF基因突变对肿瘤微环境的意义
- 批准号:
16K20968 - 财政年份:2016
- 资助金额:
$ 44.52万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Evaluation of radiation effect based on point mutation of BRAF gene
基于BRAF基因点突变的放射效果评价
- 批准号:
15K12202 - 财政年份:2015
- 资助金额:
$ 44.52万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Analysis of tumor clonality using SNPs surrounding BRAF gene and its association with clinicopathological features
BRAF基因周围SNP分析肿瘤克隆性及其与临床病理特征的关系
- 批准号:
19790651 - 财政年份:2007
- 资助金额:
$ 44.52万 - 项目类别:
Grant-in-Aid for Young Scientists (B)